GE HealthCare Technologies Inc. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
GE HealthCare reported Q2 2026 revenues of $5.3B (5.7% reported, 3.5% organic growth), with diluted EPS of $1.24 (up 16.5%) and Adjusted EPS of $1.13 (up 6.6%). The company achieved record organic orders growth of 11.1%, book-to-bill of 1.15x, and backlog of $23.9B. However, Patient Care Solutions segment revenue declined 13.3% YoY. The company reaffirmed full-year 2026 guidance: organic revenue growth of 3.0%–4.0%, Adjusted EBIT margin of 15.4%–15.7%, and Adjusted EPS of $4.80–$5.00. Notable items include $129M tariff refunds recognized in Q2 net income and CEO commentary on strategic review of PCS.
Why this rating
Q2 results modestly positive (EPS growth, record orders) but offset by PCS weakness and tariff-refund dependency. Guidance reaffirmation neutral. Mixed signals do not materially alter trajectory relative to $34B market cap.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.